Skip to main content

Table 3 Summary of results of the univariate analysis for treatment outcomes based on the candidate genotypes in the apoptosis pathway

From: Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia

Gene SNP ID Referent genotype Adverse genotype MCR CCR MMR MR4.5 LOR TF PFS OS
APAF1 rs1439123 CC/CT TT 0.803 0.393 0.233 0.085 0.011* 0.323 0.510 0.939
APAF1 rs2288713 GG/TG TT 0.747 0.886 0.617 0.530 0.812 0.992 0.271 0.863
CASP10 rs13006529 AA/TA TT 0.250 0.433 0.513 0.671 0.144 0.025* 0.311 0.019*
FASLG rs763110 TT/TC CC 0.414 0.186 0.017* 0.123 0.145 0.097 0.001** 0.020*
FAS rs1800682 TT/TC CC 0.871 0.354 0.251 0.032* 0.086 0.129 0.428 0.863
FAS rs2229521 GG/GA AA 0.856 0.688 0.748 0.863 0.600 0.384 0.600 0.685
FAS rs2234767 GG/GA AA 0.944 0.259 0.179 0.013* 0.034* 0.093 0.374 0.978
FAS rs2234978 TT/TC CC 0.026* 0.036* 0.050* 0.011* 0.379 0.089 0.409 0.535
  1. SNP single nucleotide polymorphism, MCR major cytogenetic response, CCR complete cytogenetic response, MMR major molecular response, MR4.5 complete molecular response, LOR loss of response, TF treatment failure, PFS progression free survival, OS overall survival, APAF1 apoptotic peptidase activating factor 1, CASP10 caspase 10, FAS Fas cell surface death receptor, FASLG Fas ligand (TNF receptor superfamily member 6)
  2. ** p < 0.01/* p < 0.05